Left ventricular function and collagen content after regression of hypertensive hypertrophy
- PMID: 2521332
- DOI: 10.1161/01.hyp.13.1.43
Left ventricular function and collagen content after regression of hypertensive hypertrophy
Abstract
To determine whether regression of hypertensive hypertrophy through blood pressure control also involves left ventricular collagen and consecutive alterations in left ventricular diastolic and systolic function, antihypertensive treatment with the calcium channel blocker nifedipine (30 mg/kg.day) was employed in 20-week-old spontaneously hypertensive rats (n = 15) for a period of 20 weeks. Age-matched (40 weeks old) untreated (n = 13) and 20-week-old spontaneously hypertensive rats representing the state before therapy (n = 14) were used for comparison. Myocardial stiffness was described by the tangent modulus Km of the elastic stiffness-stress relation. Left ventricular collagen was determined by means of hydroxyproline (OH-proline) concentration. Myocardial working capacity of the left ventricle was measured as the peak developed systolic pressure per weight unit muscle mass and systolic peak pump function as the maximum achievable cardiac output under volume loading. After the 20-week course of nifedipine treatment, systolic aortic pressure dropped from 187 +/- 11 to 144 +/- 6 mm Hg (p less than 0.001). Regression of hypertrophy was shown by a left ventricular muscle/body weight ratio of 2.13 +/- 0.18 mg/g (p less than 0.01) in the 40-week-old nifedipine-treated hypertensive rats, whereas the ratios of the 20-week-old and 40-week-old untreated spontaneously hypertensive rats were 2.3 +/- 0.30 and 2.34 +/- 0.18 mg/g, respectively.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Advanced hypertensive heart disease in spontaneously hypertensive rats. Lisinopril-mediated regression of myocardial fibrosis.Hypertension. 1996 Aug;28(2):269-75. doi: 10.1161/01.hyp.28.2.269. Hypertension. 1996. PMID: 8707393
-
Normal left ventricular diastolic compliance after regression of hypertrophy.J Cardiovasc Pharmacol. 1994 Mar;23(3):349-57. J Cardiovasc Pharmacol. 1994. PMID: 7515976
-
Regression of cardiac hypertrophy after therapy in animal hypertension.J Cardiovasc Pharmacol. 1985;7 Suppl 2:S56-61. doi: 10.1097/00005344-198507002-00012. J Cardiovasc Pharmacol. 1985. PMID: 2409372
-
Regression of cardiac hypertrophy with drug treatment in spontaneously hypertensive rats.Med Biol. 1984;62(5):263-76. Med Biol. 1984. PMID: 6152298 Review.
-
Regression of myocardial and coronary vascular hypertrophy in hypertensive heart disease.J Cardiovasc Pharmacol. 1988;12 Suppl 4:S45-54. doi: 10.1097/00005344-198806124-00009. J Cardiovasc Pharmacol. 1988. PMID: 2468873 Review.
Cited by
-
Therapeutic effect on left ventricular hypertrophy by different antihypertensive drugs.Clin Investig. 1992;70 Suppl 1:S87-92. doi: 10.1007/BF00207617. Clin Investig. 1992. PMID: 1534267 Review.
-
Expression of matrix metalloproteinase activity in idiopathic dilated cardiomyopathy: a marker of cardiac dilatation.Mol Cell Biochem. 2004 Sep;264(1-2):183-91. doi: 10.1023/b:mcbi.0000044387.04670.81. Mol Cell Biochem. 2004. PMID: 15544047
-
The paradox of left ventricular assist device unloading and myocardial recovery in end-stage dilated cardiomyopathy: implications for heart failure in the elderly.Heart Fail Rev. 2012 Sep;17(4-5):615-33. doi: 10.1007/s10741-012-9300-8. Heart Fail Rev. 2012. PMID: 22258830 Review.
-
Hypertension and age-related changes in the heart. Implications for drug therapy.Drugs Aging. 1994 Aug;5(2):102-15. doi: 10.2165/00002512-199405020-00004. Drugs Aging. 1994. PMID: 7981482 Review.
-
Matrix metalloproteinase activity expression in infarcted, noninfarcted and dilated cardiomyopathic human hearts.Mol Cell Biochem. 1996 Feb 9;155(1):13-21. doi: 10.1007/BF00714328. Mol Cell Biochem. 1996. PMID: 8717434
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical